



OPEN ACCESS

APPROVED BY

Luisa Lanfrancone,
European Institute of Oncology (IEO), Italy

*CORRESPONDENCE

Frontiers Editorial Office

✉ research.integrity@frontiersin.org

RECEIVED 04 October 2023

ACCEPTED 04 October 2023

PUBLISHED 19 October 2023

CITATION

Frontiers Editorial Office (2023) Retraction: Exosomes from cancer-associated mesenchymal stem cells transmit TMBIM6 to promote the malignant behavior of hepatocellular carcinoma via activating PI3K/AKT pathway. *Front. Oncol.* 13:1307333. doi: 10.3389/fonc.2023.1307333

COPYRIGHT

© 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Retraction: Exosomes from cancer-associated mesenchymal stem cells transmit TMBIM6 to promote the malignant behavior of hepatocellular carcinoma via activating PI3K/AKT pathway

Frontiers Editorial Office*

A Retraction of the Original Research Article

[Exosomes from cancer-associated mesenchymal stem cells transmit TMBIM6 to promote the malignant behavior of hepatocellular carcinoma via activating PI3K/AKT pathway](#)

by Shang C, Ke M, Liu L, Wang C, Liu Y and Zheng X (2022) *Front. Oncol.* 12:868726. doi: 10.3389/fonc.2022.868726

The Publisher retracts the cited article.

Following publication, the publisher has discovered that the authors provided false information for the peer-review process. As the scientific integrity of the article cannot be guaranteed, and adhering to the recommendations of the Committee on Publication Ethics (COPE), the publisher therefore retracts the article.

The authors have not responded to this retraction.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers.